Portfolio Receipts growth of 11% to $814 million; Royalty Receipts growth of 11%Net cash provided by operating activities of $703 millionRaised full year 2025 guidance: Portfolio Receipts expected to be $3,200 to $3,250 million NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2025 and raised full year 2025 guidance for Portfolio Receipts. “We delivered strong third quarter 2025 results, raised our full year guidance and a ...